The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Quiz|Articles|February 27, 2026
OncLive Weekly News Quiz (2/27/2026)
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA recently expanded the indication for zongertinib (Hernexeos) in HER2 tyrosine kinase domain (TKD)–mutant, metastatic nonsquamous non–small cell lung cancer (NSCLC). Which of the following best reflects the key clinical implication of the updated data from the phase 1 Beamion LUNG-1 trial (NCT04886804) that supported the accelerated approval?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Dr Akhade on Building the Evidence Base for Low-Dose Immunotherapy
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
5